[go: up one dir, main page]

SG11201405087PA - Human antibodies to clostridium difficile toxins - Google Patents

Human antibodies to clostridium difficile toxins

Info

Publication number
SG11201405087PA
SG11201405087PA SG11201405087PA SG11201405087PA SG11201405087PA SG 11201405087P A SG11201405087P A SG 11201405087PA SG 11201405087P A SG11201405087P A SG 11201405087PA SG 11201405087P A SG11201405087P A SG 11201405087PA SG 11201405087P A SG11201405087P A SG 11201405087PA
Authority
SG
Singapore
Prior art keywords
human antibodies
clostridium difficile
difficile toxins
toxins
clostridium
Prior art date
Application number
SG11201405087PA
Inventor
Anne Gurnett-Bander
Carlos Arrecubieta
Israel Lowy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11201405087PA publication Critical patent/SG11201405087PA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507Comprising a combination of two or more separate antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11201405087PA 2012-03-02 2013-03-01 Human antibodies to clostridium difficile toxins SG11201405087PA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261605914P 2012-03-02 2012-03-02
US201261608255P 2012-03-08 2012-03-08
US201261717404P 2012-10-23 2012-10-23
PCT/US2013/028630 WO2013130981A1 (en) 2012-03-02 2013-03-01 Human antibodies to clostridium difficile toxins

Publications (1)

Publication Number Publication Date
SG11201405087PA true SG11201405087PA (en) 2014-09-26

Family

ID=47844536

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201405087PA SG11201405087PA (en) 2012-03-02 2013-03-01 Human antibodies to clostridium difficile toxins
SG10201610123UA SG10201610123UA (en) 2012-03-02 2013-03-01 Human antibodies to clostridium difficile toxins

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201610123UA SG10201610123UA (en) 2012-03-02 2013-03-01 Human antibodies to clostridium difficile toxins

Country Status (18)

Country Link
US (2) US9399674B2 (en)
EP (1) EP2820044A1 (en)
JP (2) JP2015509962A (en)
KR (1) KR20140130709A (en)
CN (2) CN104203976A (en)
AR (1) AR090219A1 (en)
AU (1) AU2016203511A1 (en)
BR (1) BR112014021251A2 (en)
CA (1) CA2863536A1 (en)
HK (1) HK1200463A1 (en)
IL (1) IL233884A0 (en)
MX (1) MX2014010527A (en)
NZ (2) NZ628943A (en)
RU (2) RU2628305C2 (en)
SG (2) SG11201405087PA (en)
TW (1) TWI592422B (en)
UY (1) UY34652A (en)
WO (1) WO2013130981A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2948572T3 (en) 2009-07-08 2023-09-14 Kymab Ltd Rodent models and therapeutic molecules
EP2757875B2 (en) 2011-09-19 2023-03-22 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9181632B1 (en) 2013-09-09 2015-11-10 Merck Sharp & Dohme Corp. C.difficile toxin B CROP domain peptides, antibodies and complexes thereof
ES2993142T3 (en) 2013-10-01 2024-12-23 Kymab Ltd Animal models and therapeutic molecules
CA2976976C (en) 2015-02-19 2023-02-28 Immune Biosolutions Inc. Clostridium difficile toxins a and/or b antigen and epitope antibody, and pharmaceutical uses thereof
CA2982358A1 (en) * 2015-04-15 2016-10-20 Medimmune, Llc Methods for treating clostridium difficile infection and associated disease
CN109071665B (en) 2016-04-18 2022-11-01 塞德斯医疗公司 Agonistic antibodies that bind human CD40 and uses thereof
EP3448987A4 (en) * 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2019114804A1 (en) * 2017-12-13 2019-06-20 凯惠科技发展(上海)有限公司 Egfrviii antibody and conjugate, and preparation method and use thereof
WO2020060771A1 (en) * 2018-09-18 2020-03-26 Vanderbilt University Human monoclonal antibodies to staphylococcal aureus isd proteins and uses thereof
US20200148762A1 (en) * 2018-11-09 2020-05-14 Avamab Pharma Inc. Methods for regulating endogenous production of antibodies against infectious diseases
CN111793130B (en) * 2019-03-20 2021-09-14 华中农业大学 Haemophilus parasuis CdtB hybridoma cell and application of monoclonal antibody
KR102376876B1 (en) 2020-04-09 2022-03-21 대진대학교 산학협력단 Non-toxic Clostridium difficile toxin protein-fragments and uses thereof
WO2021219786A1 (en) * 2020-04-30 2021-11-04 Gottfried Himmler Anti-toxin secretory iga2 preparation
WO2025029561A2 (en) * 2023-07-28 2025-02-06 University Of South Florida Vaccine containing rbd2 of cdtb component from binary toxin cdt of clostridioides difficile

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879218A (en) 1982-09-13 1989-11-07 Virginia Tech Intellectual Properties, Inc. Antibody for C.difficile
US5244657A (en) 1987-11-24 1993-09-14 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5221618A (en) 1987-11-24 1993-06-22 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5332583A (en) 1987-11-24 1994-07-26 Connaught Laboratories Limited Vaccine containing genetically-detoxified pertussis holotoxin
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
US5358868A (en) 1987-11-24 1994-10-25 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5224657A (en) 1989-05-23 1993-07-06 Kabushiki Kaisha Toshiba Cryogenic refrigerator
US5231003A (en) * 1990-05-11 1993-07-27 Cambridge Bioscience Corporation Monoclonal antibodies specific for toxin b of clostridium difficile
EP0822830B1 (en) * 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
DE19739685A1 (en) 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoclonal antibodies for the therapy and prophylaxis of diseases caused by Clostridium difficile
US6214341B1 (en) 1997-10-20 2001-04-10 Oravax Passive immunization against Clostridium difficile disease
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
EP1568378B1 (en) 1997-10-20 2016-03-16 Sanofi Pasteur Biologics, LLC Immunization against Clostridium difficile disease
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
GB0309126D0 (en) 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
CN1809591A (en) * 2003-05-21 2006-07-26 米德列斯公司 Human monoclonal antibodies against bacillus anthracis protective antigen
JP4588763B2 (en) 2004-02-06 2010-12-01 ユニバーシティー オブ マサチューセッツ Antibodies against Clostridium difficile toxin and uses thereof
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
AU2005321974B2 (en) * 2004-12-27 2011-11-17 Progenics Pharmaceuticals (Nevada), Inc. Orally deliverable and anti-toxin antibodies and methods for making and using them
MX2008013451A (en) * 2006-04-17 2008-10-30 Schering Plough Ltd Recombinant attenuated clostridium organisms and vaccine.
PL2374818T3 (en) 2006-06-02 2013-05-31 Regeneron Pharma High affinity antibodies to human IL-6 receptor
WO2008014733A1 (en) * 2006-08-02 2008-02-07 Johannes Gutenberg-Universität Mainz Medicament for lct poisoning
US8035027B2 (en) 2006-10-09 2011-10-11 Solexel, Inc. Solar module structures and assembly methods for pyramidal three-dimensional thin-film solar cells
US20110020356A1 (en) 2007-12-07 2011-01-27 Lin Fang Therapeutic clostridium difficile antibody compositions
US8697374B2 (en) 2008-02-28 2014-04-15 3M Innovative Properties Company Antibodies to Clostridium difficile spores and uses thereof
WO2010094970A1 (en) 2009-02-20 2010-08-26 Health Protection Agency Antibodies to clostridium difficile toxins
MX368932B (en) 2009-06-26 2019-10-22 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format.
JP2013505289A (en) * 2009-09-23 2013-02-14 トーマス・ジュリアス・ボロディ Treatment of intestinal infections
US20120282274A1 (en) 2009-11-20 2012-11-08 Northshore University Health System Research Institute Targeting of the c-terminal segment of c.difficile toxin b for improved clinical diagnosis, prevention, and treatment
ES2547142T5 (en) 2010-02-08 2021-12-09 Regeneron Pharma Mouse common light chain
CN102947334B (en) 2010-04-15 2017-12-26 普罗杰尼克制药股份有限公司 Antibodies for the treatment of Clostridium difficile-associated infections and diseases

Also Published As

Publication number Publication date
WO2013130981A1 (en) 2013-09-06
CN108101983A (en) 2018-06-01
MX2014010527A (en) 2014-10-14
HK1200463A1 (en) 2015-08-07
SG10201610123UA (en) 2017-01-27
US20160264650A1 (en) 2016-09-15
AU2013203942A1 (en) 2013-09-19
AU2016203511A1 (en) 2016-06-16
NZ714516A (en) 2017-06-30
RU2017127772A (en) 2019-02-04
NZ628943A (en) 2016-08-26
TWI592422B (en) 2017-07-21
AU2013203942A8 (en) 2016-08-11
JP2018029625A (en) 2018-03-01
AR090219A1 (en) 2014-10-29
AU2013203942B2 (en) 2016-03-10
TW201350501A (en) 2013-12-16
RU2628305C2 (en) 2017-08-15
UY34652A (en) 2013-09-02
IL233884A0 (en) 2014-09-30
CA2863536A1 (en) 2013-09-06
RU2014139552A (en) 2016-04-20
JP2015509962A (en) 2015-04-02
KR20140130709A (en) 2014-11-11
US20130230531A1 (en) 2013-09-05
CN104203976A (en) 2014-12-10
EP2820044A1 (en) 2015-01-07
BR112014021251A2 (en) 2017-06-27
US9399674B2 (en) 2016-07-26

Similar Documents

Publication Publication Date Title
IL233884A0 (en) Human antibodies to clostridium difficile toxins
IL289241A (en) Antibodies to tau
IL235397B (en) Antibodies specific for cll-1
ZA201504898B (en) Human anti-tau antibodies
IL235042A0 (en) Anti-fcrn antibodies
IL234848A0 (en) Protease-regulated antibodies
SG11201400916XA (en) Clostridium difficile antibodies
SG11201406301TA (en) Clostridium difficile antigens
EP2861068A4 (en) Methods related to bevacizumab
IL239063A0 (en) Antibodies aganist clostridium difficile
IL233794B (en) Anti-phospholipase d4 antibody
IL237172A0 (en) פוליפפטידים של clostridium difficile כתרכיבים
EP2921502A4 (en) Human antibody specific to toxin produced from clostridium difficile, or antigen-binding fragment thereof
IL231661A0 (en) Clostridium difficile antibodies
GB0902851D0 (en) Antibodies to clostridium difficile toxins
GB0916153D0 (en) Antibodies to clostridium difficile toxins
GB201209584D0 (en) Modified antibodies